TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15613223
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg tablet during migraine (n=18)
Study: 15613223
Drug: Rizatriptan 5
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5 mg tablet in migraine-free state (n=21)
Study: 8877276
Drug: Acute metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute metformin administration (850 mg single dose)
Study: 8877276
Drug: Chronic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic metformin treatment (850 mg twice a day for a month)
Study: 1792618
Drug: nifedipine (30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (30‐60 mg/day)
Study: 1792618
Drug: aldizem (180‐270
Approvals — FDA: no, EMA: no, PMDA: no
Description: aldizem (180‐270 mg/day)
Study: 3011583
Drug: Low-dose aluminum-magnesium
Normalized name: ALUMINUM/MAGNESIUM HYDROXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aluminum-magnesium antacid regimen (Link one tablet q.i.d.)
Study: 31728609
Drug: GEWF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEWF solution
Study: 31728609
Drug: Carnoy solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnoy solution
Study: 30125815
Drug: Safety message
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety message framed in terms of the selection of water treatment technology to remove contaminants
Study: 24618485
Drug: Porous polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous polyethylene implant with mucus membrane graft (MMG)
Study: 20545210
Drug: Qianliening Tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qianliening Tang (QLNT), daily potion, two times a day for 8 weeks
Study: 20545210
Drug: Qianliekang, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianliekang, three times a day, three pills each time for 8 weeks
Study: 782463
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with naproxen and aspirin
Study: 30690848
Drug: Implant-level (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-level (IL) FPD
Study: 23782591
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors (ChEI) including donepezil, rivastigmine, and galantamine
Study: 22174580
Drug: ARB/CCB/HCTZ (valsartan/amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB/CCB/HCTZ (valsartan/amlodipine 160/5 mg + HCTZ 25 mg)
Study: 16543688
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (benazepril 1.25 to 5 mg daily or trandolapril 0.5 to 4 mg daily)
Study: 16543688
Drug: ARB (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (candesartan 2 to 8 mg daily or losartan 25 to 100 mg daily)
Study: 14633812
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aspirin or vitamin E)
Study: 1372124
Drug: Iloprost (ZK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (ZK 36 374) administered via infusion up to 12 ng kg-1 min-1 before and during ECC.
Study: 24858963
Drug: 12.6% carbohydrate-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.6% carbohydrate-containing drink (10 mL kg(‐1) the evening before surgery and two hours before anaesthesia)
Study: 18279765
Drug: Letrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (aromatase inhibitor) as initial adjuvant therapy
Study: 12466363
Drug: hypocaloric diet
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypocaloric diet + metformin
Study: 7591356
Drug: Weekly preannounced
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly preannounced urine testing
Study: 7591356
Drug: Weekly unannounced
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly unannounced urine testing
Study: 20832963
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose
Study: 28989802
Drug: Control (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (maintenance dose)
Study: 26621682
Drug: Estriol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (8 mg daily) plus glatiramer acetate (20 mg daily)
Study: 26621682
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus glatiramer acetate (20 mg daily)
Study: 21257800
Drug: PM101 Premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM101 Premixed Injection (150 mg)
Study: 17971670
Drug: Electronically stored
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronically stored nosodes treatment
Study: 27788851
Drug: Radiation doses
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation doses
Study: 12032009
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 2 mg/kg
Study: 12032009
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 1 mg/kg
Study: 12032009
Drug: Rescue analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesia (morphine patient‐controlled analgesia or oral oxycodone)
Study: 8182225
Drug: Prophylactic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic group (breast milk from mothers on an exclusion diet or extensively hydrolyzed formula, acaricide treatment, polyvinyl-covered mattresses)
Study: 31098739
Drug: Colla corii
Normalized name: CORID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colla corii asini (CCA) treatment, 15g daily for 4 weeks
Study: 27235524
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment with a double elasticated bandage for four weeks
Study: 24604461
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) in combination with systemic family therapy (SFT)
Study: 22650799
Drug: Dexmedetomidine low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine low dose (3 μg/kg/h for 10 min followed by 0.17 μg/kg/h for 50 min)
Study: 22650799
Drug: Dexmedetomidine middle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine middle dose (6 μg/kg/h for 10 min followed by 0.34 μg/kg/h for 50 min)
Study: 22650799
Drug: Dexmedetomidine high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine high dose (3.7 μg/kg/h for 35 min followed by 0.7 μg/kg/h for 25 min)
Study: 16028125
Drug: Peru-15 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peru-15 vaccine (approximately 2 x 10^8 cfu)
Study: 24156505
Drug: Brief Relational
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Relational Therapy
Study: 21726650
Drug: Mirtazapine (5-HT(2)/5-HT(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (5-HT(2)/5-HT(3) receptor antagonist)
Study: 16254269
Drug: Low-dose perfluorocarbon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose perfluorocarbon (10 ml/kg)
Study: 16254269
Drug: High-dose perfluorocarbon
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose perfluorocarbon (20 ml/kg)
Study: 15595715
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g, two 500 mg tablets)
Study: 11424117
Drug: Triple antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antigen vaccine (Hepacare) - two-dose/1-month regimen
Study: 11424117
Drug: Triple antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antigen vaccine (Hepacare) - three-dose/6-month regimen
Study: 11424117
Drug: Single antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antigen vaccine (Recombivax-HB) - three-dose/6-month regimen
Study: 11424117
Drug: Triple antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antigen vaccine (Hepacare) - three-dose/6-month regimen in at-risk adults
Study: 9024733
Drug: Simvastatin 160
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 160 mg/day
Study: 3653085
Drug: Inhalation anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthetics during bronchoscopy
Study: 3653085
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia or local anaesthesia
Study: 29540326
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rivaroxaban 2.5 mg twice daily and aspirin
Study: 23084789
Drug: DHEA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 100 mg daily
Study: 8935119
Drug: Ritipenem acoxil
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritipenem acoxil (RIPM-AC) 200 mg, t.i.d. for 14 days
Study: 8935119
Drug: Cefotiam hexetil
Normalized name: Cefotiam hexetil hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam hexetil (CTM-HE) 400 mg, t.i.d. for 14 days
Study: 6129141
Drug: Prizidilol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol 150 mg
Study: 6129141
Drug: Prizidilol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol 300 mg
Study: 6129141
Drug: Prizidilol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol 600 mg
Study: 29326421
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml 1000 IU vitamin D3-fortified milk daily for 9 weeks
Study: 29326421
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml unfortified milk daily for 9 weeks
Study: 27524680
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine titration
Study: 16128648
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine titration
Study: 2765808
Drug: Human thrombin
Normalized name: Human Thrombin
DrugBank: Human thrombin (DB11571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human thrombin (0.2-0.3 ml, 100-150 units per injection) plus 5% ethanolamine oleate
Study: 1093756
Drug: Propranolol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (640 mg daily for two months)
Study: 1093756
Drug: Diuretic induced
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic induced salt depletion
Study: 31724530
Drug: R2PHF 0.0625
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2PHF 0.0625 mg
Study: 31724530
Drug: R2PHF 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2PHF 0.25 mg
Study: 31724530
Drug: R2PHF 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2PHF 0.50 mg
Study: 31724530
Drug: R2PHF 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2PHF 1.0 mg
Study: 31724530
Drug: PHC 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHC 1.0 mg
Study: 20724982
Drug: Reamberin (energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin (energy corrector antioxidants) included in standard treatment schemes
Study: 15947324
Drug: C-Flex therapy
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Flex therapy
Study: 1884726
Drug: Spironolactone beta-cyclodextrin
Normalized name: Sulfobutylether-beta-cyclodextrin
DrugBank: Sulfobutylether-beta-cyclodextrin (DB18607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone beta-cyclodextrin complex (100 mg)
Study: 1884726
Drug: Micronised spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronised spironolactone powder (100 mg)
Study: 1884726
Drug: Spironolactone tablets
Normalized name: Spironolactone Tablets
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone tablets (Aldactone) (100 mg)
Study: 6638605
Drug: Lidoflazine therapy
Normalized name: Lidoflazine
DrugBank: Lidoflazine (DB13766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine therapy
Study: 31621274
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement melatonin (ME-group) for two months
Study: 31621274
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements melatonin, tryptophan, and vitamin B6 (MET-group) for two months
Study: 20851232
Drug: Levonorgestrel administered
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel administered in two doses of 0.75 mg given 12 h apart
Study: 20851232
Drug: Levonorgestrel administered
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel administered in a single dose of 1.5 mg
Study: 12564822
Drug: Biweekly parenting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly parenting classes and weekly meetings with a social worker
Study: 12564822
Drug: Weekly parenting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly parenting classes focusing on learning how to meet the infants' needs
Study: 9830286
Drug: Topical broad-spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical broad-spectrum antibiotics
Study: 7634175
Drug: Chronotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapy for cancer drugs; specific dosage and duration not mentioned.
Study: 2285091
Drug: Intraarticular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular bupivacaine injection at the conclusion of knee arthroscopy
Study: 7396657
Drug: Amitriptyline (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (tricyclic medication)
Study: 24656963
Drug: Carbohydrate-matching insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbohydrate-matching insulin bolus (8.30 U [7.50 U-11.50 U])
Study: 24656963
Drug: Weight-dependent insulin
Normalized name: High molecular weight insulin human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight-dependent insulin bolus (0.047 U/kg; 3.45 U [2.95 U-3.75 U])
Study: 22657838
Drug: Sodium caseinate
Normalized name: Sodium Caseinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium caseinate (Cas, 29 g)
Study: 22657838
Drug: TG‐treated sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG‐treated sodium caseinate (Cas‐TG, 29 g)
Study: 22657838
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (Wh, 30 g)
Study: 17501955
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied once daily 3 days per week for 4 weeks
Study: 11431614
Drug: Migav‐Ladach method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migav‐Ladach method (ML)
Study: 342217
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg q.i.d.
Study: 19188327
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Endovascular revascularization and Supervised exercise)
Study: 14722167
Drug: Remifentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.25 micro g kg(‐1) min(‐1)
Study: 14722167
Drug: Remifentanil 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.0 micro g kg(‐1) min(‐1) and greater
Study: 12014765
Drug: Intraumbilical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraumbilical injection of 301U oxytocin in 27mls saline
Study: 9783759
Drug: Oral iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral iloprost 50 microg
Study: 9783759
Drug: Oral iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral iloprost 100 microg
Study: 28990173
Drug: Rituximab 500
Normalized name: riTUXimab 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 500 mg/m2 every 2 weeks (for males)
Study: 28990173
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 (for females)
Study: 28990173
Drug: Upfront dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront dose-dense rituximab schedule
Study: 21331567
Drug: Intravenous ZOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ZOL 5 mg yearly
Study: 19844108
Drug: Geranylgeranylacetone (GGA)
Normalized name: geranylgeranylacetone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geranylgeranylacetone (GGA) 300 mg/day
Study: 15530193
Drug: Itraconazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (10 mg/kg orally or through a gastric tube)
Study: 15530193
Drug: Fluconazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (10 mg/kg orally or through a gastric tube)
Study: 9024026
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (ITS) 10 micrograms diluted in 1, 2, or 3 mL of normal saline
Study: 28830693
Drug: ZOSTAVAX™ (ZV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOSTAVAX™ (ZV) and quadrivalent inactivated influenza vaccine (IIV4) administered concomitantly
Study: 28830693
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine (IIV4) administered sequentially
Study: 27143689
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment with SNP analysis
Study: 24144627
Drug: GLP‐1 (7‐36)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1 (7‐36) amide infusion (1.5 pmol/kg/min)
Study: 22606064
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera cream (n = 32), applied 3 times a day for 10 days
Study: 22606064
Drug: Calendula officinalis
Normalized name: Calendula officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula officinalis ointment (n = 34), applied 3 times a day for 10 days
Study: 10886276
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lidocaine cream (ELA-Max) with alexandrite 8 mm spot size
Study: 10886276
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lidocaine cream (ELA-Max) with alexandrite 12 mm spot size
Study: 10886276
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lidocaine cream (ELA-Max) with diode 9 mm spot size
Study: 10886276
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthesia with alexandrite 12 mm spot size
Study: 10886276
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anesthesia with diode 9 mm spot size
Study: 8778198
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.1 IU/kg per day)
Study: 8778198
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone + Triiodothyronine
Study: 1726002
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of lacidipine once daily (n = 268)
Study: 1726002
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of atenolol once daily (n = 265)
Study: 1726002
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of lacidipine once daily (if needed)
Study: 1726002
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of atenolol once daily (if needed)
Study: 1726002
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 mg once daily) added if required after 2 months
Study: 6432553
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bupropion hydrochloride orally with ethanol in orange drink
Study: 6432553
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg bupropion hydrochloride orally
Study: 6432553
Drug: dummy tablet
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: dummy tablet
Study: 10648490
Drug: Atrial overdrive
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial overdrive + propafenone (600 mg/day)
Study: 8683752
Drug: Desmopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (20 to 40 mcg)
Study: 7051804
Drug: Early adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Study: 7051804
Drug: Delayed adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed adjuvant chemotherapy (5-fluorouracil, cytoxan, and prednisone)
Study: 25259737
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral preparation (single dose)
Study: 25259737
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral preparation with guaraná (single dose)
Study: 25552402
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 5 mg after ≥ 10 h fasting (Treatment A, reference)
Study: 25552402
Drug: Sublingual asenapine
Normalized name: asenapine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual asenapine 5 mg after a high‐fat meal (Treatment B)